MAPT and Alzheimer disease: MFXD can simultaneously regulate several pathways, such as the TNF signaling pathway, Calcium signaling pathway, NF-κB signaling pathway and target Tau protein-related pathology by restoring the phosphorylation level of GSK-3β to suppress abnormal hyperphosphorylation of Tau, thereby alleviating pathological damage in AD.